Advanced Peptide Science, Engineered for Purity.
PeptiNova is a reference brand in peptide science, built on purity, innovation, and scientific rigor. Every formulation follows strict quality guidelines suited to the clinical and pharmaceutical space.
Three compounds. Nine precise formulations.
PeptiNova offers 9 formulations built on 3 proprietary active compounds, RETATRUTIDE, TIRZEPATIDE, and SEMAGLUTIDE, each available in multiple dosage strengths for a range of clinical and research applications.
SEMAGLUTIDE
A GLP-1 analog that selectively activates its receptor, linked to glucose-dependent insulin secretion and reduced glucagon.
RETATRUTIDE
A triple agonist of the GIP, GLP-1 and glucagon receptors, designed to reduce appetite, increase satiety and regulate blood glucose.
TIRZEPATIDE
A dual GIP and GLP-1 receptor agonist that modulates glucose-dependent insulin secretion, glucagon and caloric intake.
Our Focus
Every PeptiNova formulation is guided by three principles: purity, innovation, and scientific rigor.
Purity.
Every formulation meets demanding pharmaceutical-grade standards, so you can rely on consistent quality across the entire line.
Innovation.
Our peptide science team continuously refines each formulation, translating research into precise and reliable products.
Rigor.
Strict internal protocols guide every formulation, so nothing is left to chance.
Science and testing behind every formulation
Every PeptiNova formulation is grounded in peer-reviewed peptide research and supported by a continuous scientific review process. Our science team continuously reviews the literature and available evidence to refine how each compound is developed and supported.
Figure 1 · Mechanism of action overview
Mechanism of action
Our three compounds act on complementary metabolic pathways: SEMAGLUTIDE selectively activates the GLP-1 receptor, TIRZEPATIDE acts as a dual GIP and GLP-1 agonist, and RETATRUTIDE simultaneously activates the GIP, GLP-1 and glucagon receptors.
| Parameter | SEMAGLUTIDE | RETATRUTIDE | TIRZEPATIDE |
|---|---|---|---|
| Molecular target | GLP-1 | GIP · GLP-1 · Glucagon | GIP · GLP-1 |
| Agonist profile | Selective | Triple | Dual |
| Strengths | 5 · 10 · 20 mg | 5 · 10 · 20 mg | 5 · 10 · 20 mg |
| Presentation | Lyophilized | Lyophilized | Lyophilized |
From compound to protocol in three steps
Select the compound
Review the profile and scientific data of SEMAGLUTIDE, RETATRUTIDE or TIRZEPATIDE.
Choose the strength
Each compound is available in 5 mg, 10 mg and 20 mg to fit the required protocol.
A complete kit
Each formulation is presented as a complete kit: lyophilized peptide vial and 2 ml Bac. water vial.
“Every formulation we release reflects the same standard: verified quality, consistent potency, and results that can be measured.”
— PeptiNova Science Team
Purity, innovation and scientific rigor.
PeptiNova was created as a reference brand in peptide science, for those who expect purity, innovation, and scientific rigor in every formulation. Each product is developed under strict quality guidelines suited to the clinical and pharmaceutical space, with a clear color coded system distinguishing each active compound and dosage strength.
From development to delivery, rigor guides every step. Advanced peptide science should be communicated clearly, with no shortcuts and no compromise.
Discover the full PeptiNova line
Three active compounds, three strengths each. Explore each formulation and its scientific profile.
[Regulatory notice — usage conditions, prescription requirements and health authority registration to be defined with legal/regulatory team.]